Luca Stingeni
University of Perugia
258 Papers
476 Citations
Luca Stingeni is an academic researcher from University of Perugia. The author has contributed to research in topics: Medicine & Atopic dermatitis. The author has an hindex of 21, co-authored 189 publications.
Chat about Author
Papers
Contact allergy to (meth)acrylates in gel nail polish in a child: An emerging risk for children.
Paolo Romita,Caterina Foti,Chiara Barlusconi,Katharina Hansel,Marta Tramontana,Luca Stingeni +5 more
TL;DR: Allergic contact dermatitis from nail (meth)acrylates has rarely been reported in adolescents and only once in a child, and nowadays nail cosmetics, mostly reported in adults.
Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance.
TL;DR: It is suggested that patients with lower BMI and shorter time to achieve PASI-100 with adalimumab standard dose were significantly more likely to be candidates for dose tapering.
Nickel Allergy: Epidemiology, Pathomechanism, Clinical Patterns, Treatment and Prevention Programs.
TL;DR: Nickel allergy is a relevant issue of public health with significant personal, social and economic impact and epidemiology, pathomechanism, clinical patterns, treatment and prevention programs are summarized.
Cutaneous necrosis in patient with antiphospholipid syndrome successfully treated with topical pimecrolimus and warfarin.
Leonardo Bianchi,Chiara Sensini,Katharina Hansel,Marta Tramontana,Paolo Romita,Roberta Giuffrida,Luca Stingeni +6 more
TL;DR: The rapid improvement of cutaneous necrosis and the favorable follow-up after warfarin introduction seem to support the hypothesis that DOACs are not effective in all APS patients and to confirm efficacy of vitamin K anticoagulant in the disease management.
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry Running title: AD management during COVID-19 pandemic
Andrea Chiricozzi,Marina Talamonti,Clara De Simone,Marco Galluzzo,Niccolò Gori,Gabriella Fabbrocini,Angelo V. Marzano,Giampiero Girolomoni,Annamaria Offidani,Maria Teresa Rossi,Luca Bianchi,Antonio Cristaudo,Maria Teresa Fierro,Luca Stingeni,Giovanni Pellacani,Giuseppe Argenziano,Annalisa Patrizi,Paolo D. Pigatto,Marco Romanelli,Paola Savoia,Pietro Rubegni,Caterina Foti,Nicola Milanesi,Anna Belloni Fortina,Maria Rita Bongiorno,Teresa Grieco,Sergio Di Nuzzo,Maria Concetta Fargnoli,Andrea Carugno,Alberico Motolese,Franco Rongioletti,Paolo Amerio,Riccardo Balestri,Concetta Potenza,Giuseppe Micali,Cataldo Patruno,Iris Zalaudek,Maurizio Lombardo,Claudio Feliciani,Lucia Di Nardo,Fabrizio Guarneri,Ketty Peris +41 more
- 21 Jan 2021
TL;DR: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treatedpatients.